Abeona Therapeutics, Inc. (ABEO)
2.585
-1.58
(-38.01%)
USD |
NASDAQ |
Nov 09, 11:58
Abeona Therapeutics Enterprise Value : 111.68M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 111.68M |
| November 05, 2026 | 96.80M |
| November 04, 2026 | 114.54M |
| November 03, 2026 | 116.26M |
| November 02, 2026 | 116.26M |
| October 30, 2026 | 121.98M |
| October 29, 2026 | 134.00M |
| October 28, 2026 | 133.42M |
| October 27, 2026 | 127.70M |
| October 26, 2026 | 119.69M |
| October 23, 2026 | 124.84M |
| October 22, 2026 | 128.85M |
| October 21, 2026 | 131.13M |
| October 20, 2026 | 136.29M |
| October 19, 2026 | 125.41M |
| October 16, 2026 | 126.56M |
| October 15, 2026 | 139.15M |
| October 14, 2026 | 122.55M |
| October 13, 2026 | 131.71M |
| October 12, 2026 | 153.45M |
| October 09, 2026 | 155.74M |
| October 08, 2026 | 156.89M |
| October 07, 2026 | 163.75M |
| October 06, 2026 | 159.75M |
| October 05, 2026 | 165.47M |
| Date | Value |
|---|---|
| October 02, 2026 | 160.89M |
| October 01, 2026 | 159.75M |
| September 30, 2026 | 173.48M |
| September 29, 2026 | 168.33M |
| September 28, 2026 | 175.77M |
| September 25, 2026 | 182.07M |
| September 24, 2026 | 183.78M |
| September 23, 2026 | 189.51M |
| September 22, 2026 | 206.10M |
| September 21, 2026 | 197.52M |
| September 18, 2026 | 191.79M |
| September 17, 2026 | 192.94M |
| September 16, 2026 | 180.35M |
| September 15, 2026 | 186.07M |
| September 14, 2026 | 183.78M |
| September 11, 2026 | 182.92M |
| September 10, 2026 | 186.64M |
| September 09, 2026 | 204.38M |
| September 08, 2026 | 207.82M |
| September 04, 2026 | 216.40M |
| September 03, 2026 | 212.40M |
| September 02, 2026 | 213.54M |
| September 01, 2026 | 215.26M |
| August 31, 2026 | 207.82M |
| August 28, 2026 | 211.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ultragenyx Pharmaceutical, Inc. | 2.491B |
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 11.38M |
| Total Expenses (Quarterly) | 31.57M |
| EPS Diluted (Quarterly) | -0.3539 |
| Gross Profit Margin (Quarterly) | 57.45% |
| Profit Margin (Quarterly) | -177.4% |
| Earnings Yield | -43.42% |
| Normalized Earnings Yield | -44.71 |